PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28845578-9	2017	This case is the second report of bypass activation conferred crizotinib resistance in a patient with NSCLC with ROS1-rearrangement, but is the first to confirm that activation of the mTOR signaling pathway leads to acquired crizotinib resistance.	Crizotinib	62-72	mechanistic target of rapamycin kinase	Homo sapiens	184-188	
30466782-7	2018	A comprehensive analysis of tyrosine phosphorylation in receptor tyrosine kinases in combination with small molecule chemical library screening revealed upregulated c-MET phosphorylation in this resistance cell line with elevated sensitivity to c-MET TKI (crizotinib) and PI3K/mTOR dual inhibitor (BEZ235).	Crizotinib	256-266	mechanistic target of rapamycin kinase	Homo sapiens	277-281	
29755689-8	2018	The ALK/MET inhibitor crizotinib enhanced the anti-tumor effect of the mTOR-inhibitor rapamycin in a patient-derived MPM xenograft with co-activated ALK/mTOR: combined therapy achieved tumor shrinkage in 4/5 tumors and growth stagnation in one tumor.	Crizotinib	22-32	mechanistic target of rapamycin kinase	Homo sapiens	71-75	
29755689-8	2018	The ALK/MET inhibitor crizotinib enhanced the anti-tumor effect of the mTOR-inhibitor rapamycin in a patient-derived MPM xenograft with co-activated ALK/mTOR: combined therapy achieved tumor shrinkage in 4/5 tumors and growth stagnation in one tumor.	Crizotinib	22-32	mechanistic target of rapamycin kinase	Homo sapiens	153-157	
33082316-0	2020	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma.	Crizotinib	54-64	mechanistic target of rapamycin kinase	Homo sapiens	23-27	
33082316-5	2020	Our analysis revealed that mTOR/Insulin signaling pathways were significantly decreased by the afatinib and crizotinib combination treatment.	Crizotinib	108-118	mechanistic target of rapamycin kinase	Homo sapiens	27-31	
29383132-0	2017	Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling.	Crizotinib	44-54	mechanistic target of rapamycin kinase	Homo sapiens	133-137	
29383132-6	2017	These results suggest that cytotoxic autophagy resulting from inhibition of c-Met/mTOR signaling may be achieved in HCC by combined NCTD and crizotinib administration.	Crizotinib	141-151	mechanistic target of rapamycin kinase	Homo sapiens	82-86	
28845578-9	2017	This case is the second report of bypass activation conferred crizotinib resistance in a patient with NSCLC with ROS1-rearrangement, but is the first to confirm that activation of the mTOR signaling pathway leads to acquired crizotinib resistance.	Crizotinib	225-235	mechanistic target of rapamycin kinase	Homo sapiens	184-188	
22987955-5	2012	Then, in the face of a strong rationale, mammalian target of rapamycin (mTOR) inhibitors are active in a proportion of PEComas (perivascular epithelioid cell tumours) and crizotinib in ALK-rearranged inflammatory myofibroblastic tumours.	Crizotinib	171-181	mechanistic target of rapamycin kinase	Homo sapiens	72-76	
24929890-3	2014	RESULTS: We identified the MNNG HOS transforming gene (MET)-anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitor crizotinib as the top hit of our drug screen, whereas compounds targeting the vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathway showed no or only minor in vitro activity.	Crizotinib	121-131	mechanistic target of rapamycin kinase	Homo sapiens	244-273	
24929890-3	2014	RESULTS: We identified the MNNG HOS transforming gene (MET)-anaplastic lymphoma receptor tyrosine kinase (ALK) inhibitor crizotinib as the top hit of our drug screen, whereas compounds targeting the vascular endothelial growth factor (VEGF) or mammalian target of rapamycin (mTOR) pathway showed no or only minor in vitro activity.	Crizotinib	121-131	mechanistic target of rapamycin kinase	Homo sapiens	275-279	
25228590-8	2014	Here, an inhibitor with potency against both mTOR and PI3K was more effective in promoting cytotoxicity when combined with crizotinib.	Crizotinib	123-133	mechanistic target of rapamycin kinase	Homo sapiens	45-49	
24556908-6	2014	Activation of autophagy in crizotinib-resistant H3122CR-1 cells involved alteration of the Akt/mTOR signaling pathway.	Crizotinib	27-37	mechanistic target of rapamycin kinase	Homo sapiens	95-99	
34729938-8	2021	2DG sensitization crizotinib might be associated with the inhibition of HK2-mediated glycolysis and P-ALK/AKT/mTOR signaling pathway in H3122 and H2228 cells.	Crizotinib	18-28	mechanistic target of rapamycin kinase	Homo sapiens	110-114	
34729938-10	2021	2DG may sensitize ALK+ NSCLC to crizotinib via suppression of HK2-mediated glycolysis and the AKT/mTOR signaling pathway.	Crizotinib	32-42	mechanistic target of rapamycin kinase	Homo sapiens	98-102